These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32209899)

  • 1. The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma.
    Rucker AJ; Raman V; Jawitz OK; Voigt SL; Harpole DH; D'Amico TA; Tong BC
    Ann Surg; 2022 Feb; 275(2):348-355. PubMed ID: 32209899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma.
    Speicher PJ; Englum BR; Ganapathi AM; Mulvihill MS; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
    J Thorac Oncol; 2015 Jan; 10(1):181-8. PubMed ID: 25490005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Adjuvant Postoperative Radiation Therapy and Chemotherapy on Survival After Esophagectomy for Esophageal Carcinoma.
    Wong AT; Shao M; Rineer J; Lee A; Schwartz D; Schreiber D
    Ann Surg; 2017 Jun; 265(6):1146-1151. PubMed ID: 27280504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
    Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease.
    Stiles BM; Mirza F; Coppolino A; Port JL; Lee PC; Paul S; Altorki NK
    Ann Thorac Surg; 2011 Aug; 92(2):491-6; discussion 496-8. PubMed ID: 21704291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer.
    Stiles BM; Christos P; Port JL; Lee PC; Paul S; Saunders J; Altorki NK
    J Thorac Cardiovasc Surg; 2010 Feb; 139(2):387-94. PubMed ID: 20006355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma.
    Groth SS; Burt BM; Farjah F; Smaglo BG; Sada YH; Sugarbaker DJ; Massarweh NN
    J Thorac Cardiovasc Surg; 2019 Apr; 157(4):1682-1693.e1. PubMed ID: 30711279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Perioperative Chemotherapy in Lymph Node-negative Esophageal Cancer After Resection: A Population-based Study With Propensity Score-matched Analysis.
    Yang Y; Zhou X; Tang L; Xu X; Du X; Qiu G
    Am J Clin Oncol; 2019 Dec; 42(12):924-931. PubMed ID: 31651453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Adjuvant Chemotherapy on Patients with Lymph Node-Positive Esophageal Cancer who are primarily Treated with Surgery.
    Pasquer A; Gronnier C; Renaud F; Duhamel A; Théreaux J; Carrere N; Gagniere J; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1340-9. PubMed ID: 26065869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
    Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma.
    Zahoor H; Luketich JD; Levy RM; Awais O; Winger DG; Gibson MK; Nason KS
    J Thorac Cardiovasc Surg; 2015 Feb; 149(2):538-47. PubMed ID: 25454907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival.
    Lutfi W; Martinez-Meehan D; Dhupar R; Christie N; Sarkaria I; Ekeke C; Baker N; Luketich JD; Okusanya OT
    J Surg Oncol; 2020 Mar; 121(4):654-661. PubMed ID: 31970776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base.
    Haque W; Verma V; Bernicker E; Butler EB; Teh BS
    Acta Oncol; 2018 Jun; 57(6):782-789. PubMed ID: 29188742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Nodal Metastases for Clinical T2N0 Esophageal Adenocarcinoma.
    Barbetta A; Schlottmann F; Nobel T; Sewell DB; Hsu M; Tan KS; Gerdes H; Shah P; Bains MS; Bott M; Isbell JM; Jones DR; Molena D
    Ann Thorac Surg; 2018 Jul; 106(1):172-177. PubMed ID: 29627387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.
    Speicher PJ; Ganapathi AM; Englum BR; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
    J Thorac Oncol; 2014 Aug; 9(8):1195-201. PubMed ID: 25157773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features.
    Moaven O; Clark CJ; Russell GB; Votanopoulos KI; Howerton R; Levine EA; Shen P
    Ann Surg; 2021 Dec; 274(6):1058-1066. PubMed ID: 31913868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.